Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

Background. Prime-boost regimens comprising ALVAC-HIV (prime) and human immunodeficiency virus type 1 (HIV) Env (boost) induce HIV-specific neutralizing antibody and cell-mediated immune responses, but the impact of boost schedule and adjuvant requires further definition. Methods. A phase 1 trial wa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: O'Connell, Robert J., Excler, Jean-Louis, Polonis, Victoria R., Ratto-Kim, Silvia, Cox, Josephine, Jagodzinski, Linda L., Liu, Michelle, Wieczorek, Lindsay, McNeil, John G., El-Habib, Raphaelle, Michael, Nelson L., Gilliam, Bruce L., Paris, Robert, VanCott, Thomas C., Tomaras, Georgia D., Birx, Deborah L., Robb, Merlin L., Kim, Jerome H.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878724/
https://ncbi.nlm.nih.gov/pubmed/26908741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiw059
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars